Characteristics | Non-CVVHDF group (nā=ā12) | CVVHDF group (nā=ā17) | P |
---|---|---|---|
Age, month | 21.0 (8.3, 23.8) | 23.0 (12.5, 24.0) | 0.372 |
Male, n | 8 | 10 | 0.717 |
Severity | Ā | Ā | 0.979 |
āStage 3, n | 7 | 10 | Ā |
āStage 4, n | 5 | 7 | Ā |
Body weight, kg | 10.6 (8.3, 14.4) | 11.0 (10.0, 14.4) | 0.565 |
Body temperature, Ā°C | 39.7 (39.4, 39.8) | 39.7 (39.3, 40.0) | 0.518 |
Heart rate, bpm | 188 (171, 195) | 187 (178, 198) | 0.982 |
LVEF, % | 38 (26, 44) | 37 (24, 47) | 0.773 |
CI, L/min/m2 | 2.89 (2.23,3.63) | 2.73 (1.92, 3.95) | 0.642 |
Systolic blood pressure, mmHg | 132.0 (76.0, 150.5) | 139 (102, 155) | 0.116 |
Acute kidney injury, n | 2 | 4 | 0.653 |
Fluid overload, n | 3 | 6 | 0.694 |
Mechanical ventilator, n | 12 | 17 | / |
Vasoactive agents | |||
āMilrinone, n | 7 | 7 | 0.462 |
āPhentolamine, n | 1 | 0 | 0.414 |
āSodium nitroprusside, n | 4 | 2 | 0.198 |
āDopamine, n | 4 | 6 | 0.913 |
āDobutamine, n | 9 | 13 | 1.000 |
āNorepinephrine, n | 1 | 3 | 0.622 |
āAdrenaline, n | 2 | 4 | 1.000 |